Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP reduced its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 35.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,414 shares of the biopharmaceutical company’s stock after selling 6,401 shares during the period. Brevan Howard Capital Management LP’s holdings in Celldex Therapeutics were worth $288,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Invesco Ltd. lifted its stake in shares of Celldex Therapeutics by 2.1% during the fourth quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company’s stock valued at $1,064,000 after buying an additional 871 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 878 shares during the last quarter. Swiss National Bank lifted its stake in shares of Celldex Therapeutics by 1.2% during the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company’s stock worth $2,964,000 after purchasing an additional 1,400 shares during the period. KBC Group NV boosted its holdings in shares of Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,647 shares during the last quarter. Finally, MetLife Investment Management LLC grew its position in shares of Celldex Therapeutics by 6.1% in the fourth quarter. MetLife Investment Management LLC now owns 39,620 shares of the biopharmaceutical company’s stock valued at $1,001,000 after purchasing an additional 2,288 shares during the period.

Celldex Therapeutics Stock Performance

Shares of NASDAQ:CLDX opened at $18.33 on Monday. The business’s 50-day simple moving average is $18.99 and its 200 day simple moving average is $22.80. The company has a market cap of $1.22 billion, a P/E ratio of -7.13 and a beta of 1.39. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). The business had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $1.08 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. Analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on CLDX shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. UBS Group cut their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a report on Friday. Morgan Stanley decreased their target price on shares of Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating on the stock in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, May 6th. Finally, Canaccord Genuity Group assumed coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They set a “buy” rating and a $64.00 price target on the stock. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $53.90.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.